Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapeutic vaccination for chronic hepatitis B: why most vaccines failed and what may work.

Antiviral research·2026
Same author

CD16<sup>+</sup> γδ T cells and antibody-dependent cellular cytotoxicity: a new axis of immune control in hepatitis B virus infection?

Gut·2026
Same author

Author Correction: DC subsets and states unraveled across human juxtatumoral and malignant tissues.

Nature immunology·2026
Same author

Recovery of HBV-specific B cell function after discontinuation of nucleos(t)ide analogue therapy: new insight and future challenges.

Gut·2026
Same author

Author Correction: DC subsets and states unraveled across human juxtatumoral and malignant tissues.

Nature immunology·2025
Same author

DC subsets and states unraveled across human juxtatumoral and malignant tissues.

Nature immunology·2025

Related Experiment Video

Updated: Jan 6, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.3K

Fine-Tuning TLR-7-Based Therapy for Functional HBV Cure.

Antonio Bertoletti1,2, Nina Le Bert1

  • 1Emerging Infectious Diseases Program Duke-NUS Medical School Singapore.

Hepatology Communications
|October 9, 2019
PubMed
Summary

This study explored a novel combination therapy for chronic Hepatitis B virus (HBV) infection. A liver-targeted Toll-like receptor 7 (TLR7) agonist plus Entecavir showed promise for a functional cure in woodchucks.

Area of Science:

  • Hepatology
  • Immunology
  • Virology

Background:

  • Chronic Hepatitis B virus (HBV) infection remains a significant global health challenge.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.6K
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

3.3K

Related Experiment Videos

Last Updated: Jan 6, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.3K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.6K
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

3.3K
  • Current therapies often achieve viral suppression but rarely a functional cure.
  • Novel therapeutic strategies are needed to enhance immune control and achieve sustained virologic remission.